Literature DB >> 21671232

Temporal bone histopathology in neurofibromatosis type 2.

Sung-Il Nam1, Fred H Linthicum, Saumil N Merchant.   

Abstract

OBJECTIVES/HYPOTHESIS: To describe the histopathologic findings in the temporal bone in patients with neurofibromatosis type 2 (NF2). The literature contains limited data on otopathology of NF2. STUDY
DESIGN: Basic science study.
METHODS: Twenty-six temporal bones from 16 patients with NF2 were examined by light microscopy. The diagnosis of NF2 was made on the basis of bilateral cochleovestibular schwannomas. Clinical information was obtained from review of the medical records.
RESULTS: The tumors were multicentric in origin in 19 of 26 (73%) ears. Typically, tumors were seen arising within the internal auditory canal and from various locations within the labyrinth. The majority of schwannomas showed high cellularity with involvement of the labyrinth. Most cases showed significant degrees of degeneration of sensory and neural elements within the cochlea. Fusion tumors were sometimes seen as a result of a schwannoma merging with an adjacent meningioma. Fifteen of 26 (58%) ears showed facial nerve involvement by schwannoma.
CONCLUSIONS: Cochleovestibular schwannomas in NF2 are aggressive neoplasms; they are often multicentric and demonstrate a propensity to involve the labyrinth. There is often associated secondary degeneration within the cochlea. These features make total removal of these tumors and their removal with preservation of hearing more difficult than with sporadic unilateral cochleovestibular schwannoma.
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21671232      PMCID: PMC3117941          DOI: 10.1002/lary.21822

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

1.  Bilateral acoustic neurinoma and neurofibromatosis.

Authors:  L F DeMoura; R C Hayden; G H Conner
Journal:  Arch Otolaryngol       Date:  1969-07

2.  Unusual audiometric and histologic findings in bilateral acoustic neurinomas.

Authors:  F H Linthicum
Journal:  Ann Otol Rhinol Laryngol       Date:  1972-06       Impact factor: 1.547

3.  Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Authors:  Scott R Plotkin; Chris Halpin; Michael J McKenna; Jay S Loeffler; Tracy T Batchelor; Fred G Barker
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

4.  Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Authors:  Scott R Plotkin; Marybeth A Singh; Caroline C O'Donnell; Gordon J Harris; Andrea I McClatchey; Chris Halpin
Journal:  Nat Clin Pract Oncol       Date:  2008-06-17

5.  Histopathology of the inner ear in unoperated acoustic neuroma.

Authors:  Mohd Ridzo Mahmud; Aayesha M Khan; Joseph B Nadol
Journal:  Ann Otol Rhinol Laryngol       Date:  2003-11       Impact factor: 1.547

Review 6.  Bilateral acoustic neurofibromatosis (neurofibromatosis 2): a disorder distinct from von Recklinghausen's neurofibromatosis (neurofibromatosis 1).

Authors:  P B Flexon; J B Nadol; H F Schuknecht; W W Montgomery; R L Martuza
Journal:  Ann Otol Rhinol Laryngol       Date:  1991-10       Impact factor: 1.547

7.  Histopathology of 30 non-operated acoustic schwannomas.

Authors:  L Eckermeier; W Pirsig; D Mueller
Journal:  Arch Otorhinolaryngol       Date:  1979

8.  Bilateral acoustic tumors. A diagnostic and surgical challenge.

Authors:  F H Linthicum; D E Brackmann
Journal:  Arch Otolaryngol       Date:  1980-12

9.  Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases.

Authors:  R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more
  7 in total

1.  Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.

Authors:  Nicolas -Xavier Bonne; Rabih Aboukais; Marc Baroncini; Audrey Hochart; Pierre Leblond; Franck Broly; Frédérique Dubrulle; Jean-Paul Lejeune; Christophe Vincent
Journal:  Childs Nerv Syst       Date:  2016-10-04       Impact factor: 1.475

2.  Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance.

Authors:  Joni Doherty; John L Go; Fred H Linthicum
Journal:  Otol Neurotol       Date:  2014-10       Impact factor: 2.311

3.  An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.

Authors:  Nicolas-Xavier Bonne; Jérémie Vitte; Fabrice Chareyre; Gevorg Karapetyan; Vazgen Khankaldyyan; Karo Tanaka; Rex A Moats; Marco Giovannini
Journal:  J Neurooncol       Date:  2016-05-13       Impact factor: 4.130

Review 4.  Cochlear histopathology in human genetic hearing loss: State of the science and future prospects.

Authors:  Krishna Bommakanti; Janani S Iyer; Konstantina M Stankovic
Journal:  Hear Res       Date:  2019-08-19       Impact factor: 3.208

Review 5.  Intratemporal facial nerve schwannoma: clinical presentation and management.

Authors:  Ghizlene Lahlou; Yann Nguyen; Francesca Yoshie Russo; Evelyne Ferrary; Olivier Sterkers; Daniele Bernardeschi
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-16       Impact factor: 2.503

6.  Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Authors:  Stavros M Stivaros; Anat O Stemmer-Rachamimov; Robert Alston; Scott R Plotkin; Joseph B Nadol; Alicia Quesnel; Jennifer O'Malley; Gillian A Whitfield; Martin G McCabe; Simon R Freeman; Simon K Lloyd; Neville B Wright; John-Paul Kilday; Ian D Kamaly-Asl; Samantha J Mills; Scott A Rutherford; Andrew T King; D Gareth Evans
Journal:  J Med Genet       Date:  2015-06-23       Impact factor: 6.318

7.  Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation.

Authors:  Alyssa Brown; Samuel Early; Sasa Vasilijic; Konstantina M Stankovic
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.